{"id":"W4225252886","doi":"10.1080/10428194.2022.2057484","title":"A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Atezolizumab; Medicine; Internal medicine; Cohort; Myeloid leukemia; Adverse effect; Myeloid; Gastroenterology; Phases of clinical research; Oncology; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001018888,0.0009797711,0.001278599,0.0003136981,0.0002164846,0.0004787351,0.0004894016,0.0007921944,0.001760002],"category_scores_gemma":[0.0006395128,0.0003331012,0.0006816955,0.0002346711,0.000373333,0.0003940222,0.0002324527,0.001924655,0.00043013],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003684135,"about_ca_system_score_gemma":0.0006971027,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003689766,"about_ca_topic_score_gemma":0.001097025,"domain_scores_codex":[0.9997604,0.0001325373,0.00001690413,0.00003730754,0.00001933106,0.00003351103],"domain_scores_gemma":[0.999666,0.00006443589,0.00009383543,0.00002638247,0.00002367945,0.0001257067],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4590302,0.07442877,0.009719686,0.001834829,0.001660184,0.0005966138,0.0003515211,0.003651278,0.1620882,0.0005318369,0.003943463,0.2821633],"study_design_scores_gemma":[0.3630036,0.6020351,0.01468417,0.00007559475,0.0004052876,0.0008216575,0.00004695813,0.001432884,0.0110531,0.0001824173,0.006224229,0.00003483942],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912181,0.003983874,0.0008571865,0.0003505346,0.00008955625,0.00173733,0.0006492992,0.0000632803,0.001050866],"genre_scores_gemma":[0.9887103,0.003346675,0.002506619,0.0006185901,0.0001171665,0.001345588,0.001358815,0.00002253152,0.001973592],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001760002,"threshold_uncertainty_score":0.005887806,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0187460752094946,"score_gpt":0.2970652983249665,"score_spread":0.2783192231154719,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}